Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Patients whose data were accessible for research purposes during the study observation period.
2. Patients diagnosed with CML-CP at first recorded diagnosis of CML.
3. Patients ≥ 18 years of age at first recorded diagnosis of CML.
4. Patients who initiated qualifying 1L therapy for CML-CP during the study identification period. Qualifying 1L therapy treatments consisted of imatinib, dasatinib, bosutinib, or nilotinib as monotherapy.
5. Patients with ≥1 visit within The US Oncology Network practices following initiation of 1L therapy and through the end of the study observation period.
You may not be if
1. Patients enrolled in interventional clinical trials during the study observation period.
2. Patients who received any systemic treatment indicated for another primary cancer during the study observation period.
Clareo Health | Treatment Patterns and Key Endpoints Among Patients With Chronic-Phase Chronic Myeloid Leukemia in a Community Oncology Setting
